BB Biotech (BION.SW) Stock Price
BB Biotech Price
Revenue at BB Biotech has contracted by 7.2% per year over the past 19 years to 76.81 M CHF. Earnings per share have grown at 7.8% per year over the last 19 years. BB Biotech's net margin stands at 752.7%, up from 102.2% several years earlier. BB Biotech currently offers a dividend yield of about 7.79%. The payout ratio is around 17% of earnings. The dividend has grown at 11.6% per year over the past 15 years. Analysts set a median price target of 58.87 CHF, implying 19.8% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
BB Biotech stock price
BB Biotech business model & stock analysis
Frequently asked questions about BB Biotech
BB Biotech AG is a biotechnology investment company headquartered in Switzerland. The company primarily focuses on investing in a portfolio of innovative and promising biotechnology companies, with a particular emphasis on companies developing and commercializing breakthrough therapies. BB Biotech AG aims to support and generate long-term value by investing in cutting-edge biotech companies that address unmet medical needs and have strong growth potential. By leveraging their extensive expertise and network within the biotech industry, BB Biotech AG aims to provide investors with an attractive investment opportunity in the rapidly evolving field of biotechnology.
BB Biotech AG is primarily active in the biotechnology industry.
Some of the main competitors of BB Biotech AG in the market include Roche Holding AG, Novartis AG, and Johnson & Johnson.
BB Biotech AG is a renowned Swiss investment company specializing in the healthcare sector. Established in 1993, BB Biotech has a rich history of success in generating long-term value for its shareholders. The company primarily focuses on investing in innovative biotech companies that exhibit strong growth potential. BB Biotech benefits from an experienced team of professionals dedicated to thoroughly assessing and selecting promising investment opportunities within the biotech industry. With its extensive expertise and broad network, BB Biotech seeks to capitalize on cutting-edge advancements in the healthcare sector. Throughout its history, BB Biotech has consistently delivered impressive returns for investors, solidifying its position as a leading player in the biotech investment space.
BB Biotech AG has achieved significant milestones in its history. Some notable achievements include the successful launch of its investment strategy focused on globally listed biotech companies. The company has also been able to deliver consistent returns to its shareholders, with a strong track record of portfolio performance. BB Biotech AG has established itself as a leader in the biotech sector, with a well-diversified portfolio of investments in innovative companies. The company has also been actively involved in supporting the development of breakthrough therapies and advancements in the biotech industry. Overall, BB Biotech AG's achievements reflect its commitment to supporting the growth and success of the biotech sector.
BB Biotech AG is primarily present in Switzerland and Germany.
BB Biotech AG represents strong values and a solid corporate philosophy. As a leading biotech investment company, BB Biotech AG focuses on long-term capital appreciation through investments in the biotechnology industry. They strive to support innovative companies that develop cutting-edge therapies and healthcare solutions. This strategy aligns with their commitment to drive advancements and improvements in the healthcare sector. By investing in emerging biotech companies with significant growth potential, BB Biotech AG aims to generate sustainable returns for its shareholders.
Analysts currently set an average price target of 58.28 CHF for the BB Biotech stock (median: 58.87 CHF), implying +18.6 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the BB Biotech stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BB Biotech to generate revenue of 1.28 B CHF and earnings per share of 2.57 CHF.
Converted at the current exchange rate, the BB Biotech share trades at 52.80 EUR (49.15 CHF).
The BB Biotech share (BION.SW) is listed on 6 stock exchanges, including: London (0JYO.L), SIX (Zürich) (BION.SW), XETRA (BBZA.DE), München (BBZA.MU), Düsseldorf (BBZA.DU), Hamburg (BBZA.HM).
BB Biotech AG is a Swiss investment company specializing in biotechnology. The company actively invests worldwide in biotechnology companies working on innovative therapies to combat various diseases. Their approach focuses on companies developing medications and therapies based on genomic and protein research. The business model of BB Biotech AG is based on their position as strong and experienced investors in the biotechnology field. They invest in a variety of companies within their portfolio that focus on the development of innovative therapeutic options. The company strives for long-term success by investing in companies that utilize innovative technologies for drug manufacturing. BB Biotech AG is a key player in the global biotech market and a significant investor in this sector. In addition to their investment strategy, BB Biotech AG also offers comprehensive consulting services and expertise in the biotechnology and life sciences field. The company supports biotechnology companies in various stages of development, from research and development to drug approval and marketing. Their portfolio includes companies from various areas of biotechnology and life sciences, including biopharmaceuticals, diagnostics, medical technology, and genomics. Some of the key companies in their portfolio are Biotechnology Innovation Organization, Regeneron Pharmaceuticals, Gilead Sciences, Vertex Pharmaceuticals, and Blueprint Medicines. The company aims to actively manage and optimize their portfolio to provide investors with the highest benefit. Through careful research, analysis, and monitoring of biotechnology markets worldwide, BB Biotech AG is able to identify opportunities and act in a timely manner. Overall, BB Biotech AG offers an innovative business model based on a deep understanding of the biotechnology industry and a comprehensive portfolio of companies utilizing innovative technologies for drug manufacturing. The company provides comprehensive investment and consulting services and is a major player in the global biotech market.
The expected revenue of BB Biotech is 1.28 B CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BB Biotech is 141.47 M CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BB Biotech is currently 19.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BB Biotech stock.
The price-to-sales ratio (P/S) of BB Biotech is currently 2.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BB Biotech stock.
The Eulerpool Quality Score for BB Biotech is 4/10.
The ISIN of BB Biotech is CH0038389992. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BB Biotech is A0NFN3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BB Biotech is BION.SW. The ticker symbol is used to trade BB Biotech shares on the stock exchange.
BB Biotech stock
BB Biotech Peer Group
BB Biotech Ticker
BB Biotech FIGI
All fundamentals and in-depth analysis of BB Biotech
Our stock analysis for BB Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BB Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.